Berner M M, Hagen M, Kriston L
Abt. Psychiatrie und Psychotherapie, Klinikum der Albert-Ludwigs-Universitaet, Hauptstrasse 5, Freiburg im Breisgau, Germany, D-79104.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003546. doi: 10.1002/14651858.CD003546.pub2.
Psychotropic drugs are associated with sexual dysfunction. Symptoms may concern penile erection, lubrication, orgasm, libido, sexual arousal or overall sexual satisfaction.
To determine the effects of different strategies (e.g. dose reduction, drug holidays, adjunctive medication, switching to another drug) for treatment of sexual dysfunction due to antipsychotic therapy.
We searched the Cochrane Schizophrenia Group's Register (June 2006), the Cochrane Library (Issue 2, 2005), MEDLINE (1966-8/2005), PsycLIT (1974-8/2005), EMBASE (1980-8/2005) and references of all identified studies for further trials. We contacted relevant pharmaceutical companies and authors of trials.
We included all relevant randomised controlled trials involving people with schizophrenia and sexual dysfunction.
Working independently, we extracted data. For dichotomous data we calculated random effects odds ratios (OR) with 95% confidence intervals (CI) and, where appropriate, the number needed to treat (NNT) on an intention-to-treat basis. For continuous data we calculated weighted mean differences on the basis of a random effects model. We analysed crossover trials under consideration of correlation of paired measures.
Currently this review includes two pioneering crossover studies (total n=42 men, duration 2-3 weeks). They reported significantly more erections sufficient for penetration when receiving sildenafil compared with when receiving placebo (n=32, WMD 3.20 CI 1.83 to 4.57), a greater mean duration of erections (n=32, WMD 1.18 CI 0.52 to 1.84) and frequency of satisfactory intercourse (n=32, WMD 2.84 CI 1.61 to 4.07). The second trial found no evidence for selegiline as symptomatic treatment for antipsychotic-induced sexual dysfunction compared with placebo (n=10, WMD change on Aizenberg's sexual functioning scale -0.40 CI -3.95 to 3.15).
AUTHORS' CONCLUSIONS: We are not confident that crossover studies are appropriate for this participant group. Sildenafil may be a useful option in the treatment of antipsychotic-induced sexual dysfunction in men with schizophrenia, but this conclusion is based only on one small short trial. Further well designed, conducted and reported trials are urgently needed.
精神药物与性功能障碍有关。症状可能涉及阴茎勃起、润滑、性高潮、性欲、性唤起或总体性满意度。
确定不同策略(如剂量减少、药物假期、辅助用药、换用另一种药物)治疗抗精神病药物治疗所致性功能障碍的效果。
我们检索了Cochrane精神分裂症研究组注册库(2006年6月)、Cochrane图书馆(2005年第2期)、MEDLINE(1966年至2005年8月)、PsycLIT(1974年至2005年8月)、EMBASE(1980年至2005年8月)以及所有已识别研究的参考文献以查找进一步的试验。我们联系了相关制药公司和试验作者。
我们纳入了所有涉及精神分裂症患者和性功能障碍的相关随机对照试验。
我们独立提取数据。对于二分数据,我们计算意向性分析基础上的随机效应比值比(OR)及95%置信区间(CI),并在适当情况下计算需治疗人数(NNT)。对于连续性数据,我们基于随机效应模型计算加权均数差值。我们在考虑配对测量相关性的情况下分析交叉试验。
目前本综述纳入了两项开创性的交叉试验(共42名男性,持续时间2 - 3周)。他们报告称,与接受安慰剂时相比,接受西地那非时阴茎勃起足以进行性交的情况显著更多(n = 32,加权均数差值3.20,CI 1.83至4.57),勃起平均持续时间更长(n = 32,加权均数差值1.18,CI 0.52至1.84),满意性交频率更高(n = 32,加权均数差值2.84,CI 1.61至4.07)。第二项试验未发现与安慰剂相比,司来吉兰作为抗精神病药物所致性功能障碍对症治疗的证据(n = 10,艾森伯格性功能量表上的加权均数差值变化 - 0.40,CI - 3.95至3.15)。
我们不确定交叉试验是否适用于该参与者群体。西地那非可能是治疗精神分裂症男性抗精神病药物所致性功能障碍的一个有用选择,但这一结论仅基于一项小型短期试验。迫切需要进一步设计良好、实施得当且报告规范的试验。